TP53 and prostate cancer: Work by I. Ben Sahra and colleagues demonstrated that metformin induces expression of REDD1 (also known as DDIT4), a negative regulator of mTOR, and inhibits proliferation of human prostate cancer cell lines in a p53-dependent manner [18].